MOA SPECIFICS Flashcards
MOA of metformin
Suppression of hepatic glucose production & absorption
Increase insulin sensitivity by peripheral tissues & GLP-1 synthesis
Unusual adverse effects of metformin
VIT B12 deficiency
Lactic Acidosis
Sulfonylureas end in
IDE
Sulfonylureas require
Beta cell function so ineffective in Type 1
Unusual side effects of Sulfonylureas
Therapy failure
HYPOGLYCEMIA, which is more severe
Higher risk with malnutrition, greater than 60, abx
MOA of Sulfonylureas
Inhibits K+ ATP on BETA CELLS
Ca+ enters, Insulin leaves
TZDs end in
GLITAZONE
MOA of TZDs
Increases insulin sensitivity at skeletal muscle, hepatic & adipose tissue & glucose use
Decreases insulin resistance & hepatic glucose production
TZDs decrease
Triglycerides
GLP-1 receptor agonists ends in
TIDE
MOA of GLP-1 receptor agonist
Increases beta cell insulin secretion & satiety
Decreases alpha cell glucagon production & appetite
Unusual side effects of GLP-1 receptor agonist
Acute pancreatitis & renal insufficiency
Injection site reaction
Gallbladder & biliary disease risk
Sodium glucose co transporter inhibitors end in
GLIFLOZIN
MOA of Sodium glucose co transporter inhibitors
Inhibits SGLT2 in the proximal tubule
Sodium glucose co transporter inhibitors cause
A decrease in BP & decrease CV EVENTS
What to consider with SGLT2 inhibitors
Ketoacidosis & dehydration
Unusual side effects of SGLT2 inhibitors
Osmotic diuresis
Higher risk in ACEI & ARBs
Ketoacidosis
UTI & genital infections
Decrease bone density
Dipeptidyl-peptidase inhibitors end in
GLIPTIN
MOA of dipeptidyl-peptidase 4 inhibitors
Inhibits DPP4 enzyme which breaks down incretin hormones
Increase insulin secretion
Decrease glucagon secretion
DPP4 Inhibitors cause
Musculoskeletal pain
MOA of thionamides
Inhibits thyroid peroxidase & formation of TH
Decrease concentrations of antithyrotropin- receptor antibodies
PTU inhibits deiodination of T4-T3
Adverse effects of Thionamides
Urticaria
Skin rash
Arthralgia
GI discomfort
Agranulocytosis & granulocytopenia
Hepatic toxicity